Alzheimer's disease

News

Lilly's tau drug for Alzheimer's flunks phase 2 test

Eli Lilly is still celebrating the FDA approval of its amyloid-directed Alzheimer's therapy Kisunla but has had less fortune with a candidate against tau, another well-established drug targ

News

After EU setback, Eisai/Biogen build case for Leqembi

Eisai and Biogen have reported data showing that the benefit of treatment with their Alzheimer's disease therapy Leqembi appears to build over time, with no increase in safety risks.

News

Conceptual image of cogs turning in the human brain

Older GLP-1 drug shows glimmer of benefit in Alzheimer's

It's possible that Alzheimer's disease could be added to the lengthening list of health conditions that can be improved by treatment with GLP-1 receptor agonists.

News

Cognition Therapeutics' chief executive Lisa Ricciardi

Cognition's SHINE data for Alzheimer's drug dulls prospects

Cognition Therapeutics has reported phase 2 data with its Alzheimer's disease candidate, claiming the results show proof-of-concept for the drug, although the study missed its main endpoint

News

In shock move, EU panel rejects Alzheimer's drug Leqembi

The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China, and Japan gave a green lig

News